[1] |
Ebata T, Ercolani G, Alvaro D, et al. Current status on cholangiocarcinoma and gallbladder cancer[J]. Liver Cancer, 2016, 6(1):59-65
|
[2] |
Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(9):557-588.
|
[3] |
Kasumova GG, Tabatabaie O, Najarian RM, et al. Surgical management of gallbladder cancer: simple versus extended cholecystectomy and the role of adjuvant therapy[J]. Ann Surg, 2017, 266(4):625-631.
|
[4] |
Mitin T, Enestvedt CK, Jemal A, et al. Limited use of adjuvant therapy in patients with resected gallbladder cancer despite a strong association with survival[J]. J Natl Cancer Inst, 2017, 109(7): djw324.
|
[5] |
Ma N, Cheng H, Qin B, et al. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis[J]. BMC Cancer, 2015(15):615.
|
[6] |
Hoehn RS, Wima K, Ertel AE, et al. Adjuvant therapy for gallbladder cancer: an analysis of the national cancer database[J]. J Gastroint Surg, 2015, 19(10):1794-1801.
|
[7] |
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14):1273-1281.
|
[8] |
Personeni N, Lleo A, Pressiani T, et al. Biliary tract cancers: molecular heterogeneity and new treatment options[J]. Cancers,2020, 12(11):3370.
|
[9] |
Lamarca A, Barriuso J, McNamara MG, et al. Molecular targeted therapies: ready for "prime time" in biliary tract cancer[J]. J Hepatol, 2020, 73(1):170-185.
|
[10] |
Ilyas FZ, Beane JD, Pawlik TM. The state of immunotherapy in hepatobiliary cancers[J]. Cells, 2021, 10(8):2096.
|
[11] |
Chakrabarti S, Kamgar M, Mahipal A. Targeted therapies in advanced biliary tract cancer: an evolving paradigm[J]. Cancers, 2020, 12(8):2039.
|
[12] |
Rizzo A, Ricci AD, Cusmai A, et al. Systemic treatment for metastatic biliary tract cancer: state of the art and a glimpse to the future[J]. Curr Oncol, 2022, 29(2):551-564.
|
[13] |
Chen X, Wu X, Wu H, et al. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phaseⅡ trial[J]. J Immunother Cancer, 2020, 8(2):e001240.
|
[14] |
Feng K, Liu Y, Zhao Y, et al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phaseⅡstudy[J]. J Immunother Cancer, 2020, 8(1):e000367.
|
[15] |
Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study[J]. Lancet Oncol, 2010, 11(12):1142-1148.
|
[16] |
Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study[J]. Lancet Oncol, 2010, 11(1):48-54.
|
[17] |
Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open label, phase 2 study[J]. Lancet Oncol, 2020, 21(5):671-684.
|
[18] |
Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicenter, randomized, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(6):796-807.
|
[19] |
Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phaseⅡ trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase Ⅱ consortium study[J]. J Clin Oncol, 2010, 28(21):3491-3497.
|
[20] |
Demols A, Borbath I, Van den Eynde M, et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase Ⅱ trial[J]. Ann Oncol, 2020, 31(9):1169-1177.
|
[21] |
Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6(6):888-894.
|